Massimo Aglietta
#149,627
Most Influential Person Now
Researcher ORCID ID = 0000-0002-2255-7972
Massimo Aglietta's AcademicInfluence.com Rankings
Massimo Agliettaphysics Degrees
Physics
#6598
World Rank
#8562
Historical Rank
Particle Physics
#317
World Rank
#334
Historical Rank

Download Badge
Physics
Massimo Aglietta's Degrees
- PhD Physics University of Milan
- Masters Physics University of Milan
- Bachelors Physics University of Milan
Why Is Massimo Aglietta Influential?
(Suggest an Edit or Addition)Massimo Aglietta's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial (2012) (1608)
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. (2018) (1231)
- Granulocyte- and granulocyte– macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate (1989) (642)
- Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. (2007) (570)
- A comparison of allografting with autografting for newly diagnosed myeloma. (2007) (510)
- Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. (1997) (460)
- The release of platelet-activating factor from human endothelial cells in culture. (1983) (411)
- Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. (2001) (334)
- Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. (1999) (300)
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. (2012) (297)
- Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow (2006) (286)
- Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. (2015) (253)
- Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging (2004) (236)
- Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. (1981) (219)
- Interleukin 1 stimulates platelet activating factor production in cultured human endothelial cells. (1986) (210)
- Correlations between diffusion-weighted imaging and breast cancer biomarkers (2012) (208)
- Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. (1987) (171)
- PARP Inhibitors in Ovarian Cancer. (2018) (169)
- Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma (2006) (166)
- Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas (2010) (164)
- Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways (2009) (160)
- Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort (2014) (157)
- Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. (2013) (157)
- Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. (1989) (144)
- High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. (2002) (143)
- Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival (2006) (143)
- Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors (2012) (141)
- Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation (1998) (138)
- Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. (2011) (133)
- Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. (2005) (126)
- Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. (2006) (126)
- First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study (2021) (119)
- Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study) (2016) (116)
- Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. (2010) (113)
- Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. (2008) (111)
- Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. (1995) (107)
- Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity (2007) (103)
- NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. (2019) (101)
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. (2014) (101)
- The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models (2013) (101)
- Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. (2011) (97)
- Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme (2014) (96)
- Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. (2012) (92)
- Metastatic breast cancer subtypes and central nervous system metastases. (2014) (92)
- Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient. (2002) (90)
- Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer (2011) (89)
- Human endothelial cells are targets for platelet-activating factor (PAF). Activation of alpha and beta protein kinase C isozymes in endothelial cells stimulated by PAF. (1994) (88)
- Ex vivo expansion of human adult stem cells capable of primary and secondary hemopoietic reconstitution. (2003) (88)
- Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. (1995) (87)
- Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. (2004) (81)
- Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors (2008) (81)
- Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features (2013) (80)
- Combined first‐stage hepatectomy and colorectal resection in a two‐stage hepatectomy strategy for bilobar synchronous liver metastases (2010) (80)
- Induction gemcitabine and oxaliplatin therapy followed by a twice‐weekly infusion of gemcitabine and concurrent external‐beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer (2013) (79)
- Translocation-related sarcomas. (2009) (78)
- GAS6 inhibits granulocyte adhesion to endothelial cells. (1998) (78)
- TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. (2005) (77)
- Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity (2017) (75)
- The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma (2005) (73)
- Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases (2006) (72)
- Evolution of the Experimental Models of Cholangiocarcinoma (2020) (72)
- Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. (2013) (70)
- Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer (2014) (70)
- GAS6, the ligand of Axl and Rse receptors, is expressed in hematopoietic tissue but lacks mitogenic activity. (1997) (70)
- Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). (2018) (67)
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. (2014) (66)
- Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study (2011) (66)
- TGFα expression impairs Trastuzumab-induced HER2 downregulation (2005) (65)
- Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. (2014) (65)
- Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer (2007) (64)
- Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. (2012) (64)
- Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells (1986) (64)
- The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study. (2012) (62)
- Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? (2016) (61)
- Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. (1996) (60)
- Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis (2007) (60)
- Biosynthesis and release of platelet-activating factor from human monocytes. (1983) (60)
- International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). (2011) (57)
- In vitro and in vivo megakaryocyte differentiation of fresh and ex-vivo expanded cord blood cells: rapid and transient megakaryocyte reconstitution. (2003) (57)
- Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. (2010) (56)
- Hormone‐receptor expression and activity of trastuzumab with chemotherapy in HER2‐positive advanced breast cancer patients (2012) (56)
- Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer. (2016) (55)
- Insensitivity of chronic myeloid leukemia cells to inhibition of growth by prostaglandin E1. (1980) (54)
- In vivo effect of human granulocyte-macrophage colony-stimulating factor on megakaryocytopoiesis. (1991) (54)
- Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. (2009) (54)
- HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib (2011) (54)
- Trastuzumab-based combination therapy for breast cancer (2004) (52)
- Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. (2018) (52)
- Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells. (1985) (51)
- Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation (2009) (50)
- Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications (2019) (49)
- Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. (2006) (49)
- A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer (2004) (49)
- Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142. (2018) (47)
- Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity? (2011) (47)
- Safety and Activity of Docetaxel and Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer: A Pilot Phase II Study (2003) (47)
- Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 (2018) (47)
- Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. (2021) (47)
- Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. (2017) (46)
- Phase II Trial of Primary Radiation Therapy and Concurrent Chemotherapy for Patients with Locally Advanced Pancreatic Cancer (2005) (45)
- Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update. (2020) (45)
- PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models (2017) (45)
- Next generation immune-checkpoints for cancer therapy. (2018) (45)
- Diagnostic accuracy of portal-phase CT and MRI with mangafodipir trisodium in detecting liver metastases from colorectal carcinoma. (2007) (43)
- Activation of JAK2 in human vascular endothelial cells by granulocyte-macrophage colony-stimulating factor. (1997) (43)
- Biliary tract carcinomas: from chemotherapy to targeted therapy. (2013) (43)
- High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. (2006) (43)
- No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. (2011) (42)
- HEMATOPOIESIS Engraftment in Nonobese Diabetic Severe Combined Immunodeficient Mice of Human CD 34 1 Cord Blood Cells After Ex Vivo Expansion : Evidence for the Amplification and Self-Renewal of Repopulating Stem Cells (1999) (42)
- Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer (2014) (42)
- Poor prognosis osteosarcoma: new therapeutic approach (2008) (41)
- Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125FAK) in human endothelial cells. (1996) (40)
- A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet‐derived growth factor receptor‐α or ‐β (2011) (39)
- Negative influence of IL3 on the expansion of human cord blood in vivo long-term repopulating stem cells. (2000) (39)
- The prognostic nutritional index predicts survival and response to first‐line chemotherapy in advanced biliary cancer (2019) (38)
- A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. (2004) (38)
- Interaction of transforming growth factor-beta 1 with hemopoietic growth factors in the regulation of human normal and leukemic myelopoiesis. (1989) (37)
- PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072). (2011) (37)
- Fast But Durable Megakaryocyte Repopulation and Platelet Production in NOD/SCID Mice Transplanted with Ex‐Vivo Expanded Human Cord Blood CD34+ Cells (2004) (37)
- TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. (2015) (36)
- Responsiveness of highly enriched CFU-GM subpopulations from bone marrow, peripheral blood, and cord blood to hemopoietic growth inhibitors. (1991) (36)
- The effects of human FLT3 ligand on in vitro human megakaryocytopoiesis. (1996) (35)
- Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation (2016) (35)
- Recent advances in the development of breast cancer vaccines (2014) (34)
- Studies on the mechanism of interleukin 1 stimulation of platelet activating factor synthesis in human endothelial cells in culture. (1987) (34)
- Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. (2012) (34)
- Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases (2013) (33)
- Effect of acidic and basic isoferritins on in vitro growth of human granulocyte-monocyte progenitors. (1986) (33)
- Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma. (2005) (33)
- CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy (2019) (33)
- Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient (2015) (33)
- Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer (2005) (32)
- CD44v6 as innovative sarcoma target for CAR-redirected CIK cells (2018) (32)
- A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer (2005) (32)
- COVID-19 Emergency and the Need to Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice. (2020) (32)
- Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen (2016) (32)
- Adoptive immunotherapy against ovarian cancer (2016) (32)
- Genitourinary tumors, non-prostate (2012) (31)
- Fluoropyrimidine-induced cardiotoxicity. (2018) (31)
- Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. (2012) (31)
- Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. (2009) (31)
- Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up. (2019) (30)
- Ex vivo expansion of hematopoietic cells and their clinical use. (1998) (30)
- Short‐term administration of granulocyte‐macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs (1993) (30)
- HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. (2003) (30)
- Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. (2008) (29)
- Interleukin-3 in vivo : kinetic of response of target cells (1993) (29)
- Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells (2016) (29)
- The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients (2006) (28)
- Relevance of recruitment-synchronization in the scheduling of 1-beta-D-arabinofuranosylcytosine in a slow-growing acute myeloid leukemia of the rat. (1979) (28)
- Detection of basophils growing in semisolid agar culture. (1981) (28)
- Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update. (2020) (28)
- Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours (2019) (28)
- Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. (2003) (28)
- Outcome of Metastatic Colorectal Cancer: Analysis of a Consecutive Series of 229 Patients. The Impact of a Multidisciplinary Approach (2006) (27)
- Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142. (2018) (27)
- Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. (1986) (27)
- Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. (2009) (27)
- Continuation of trastuzumab beyond disease progression. (2005) (27)
- Expression of the c‐ErbB‐2/HER2 proto‐oncogene in normal hematopoietic cells (2003) (27)
- Screening for the FIG‐ROS1 fusion in biliary tract carcinomas by nested PCR (2014) (26)
- Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. (2015) (26)
- Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. (2021) (26)
- Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. (2005) (26)
- Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry (2013) (26)
- Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. (2009) (26)
- Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach? (2021) (26)
- Involvement of a serine protease in the synthesis of platelet‐activating factor by endothelial cells stimulated by tumor necrosis factor‐α or interleukin‐1α (1994) (26)
- Human gamma interferon enhances release from phytohemagglutinin-stimulated T4+ lymphocytes of activities that stimulate colony formation by granulocyte-macrophage, erythroid, and multipotential progenitor cells. (1986) (26)
- Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. (2014) (25)
- 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. (2012) (25)
- Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. (2017) (25)
- A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients (2013) (25)
- Different growth factor requirements for the ex vivo amplification of transplantable human cord blood cells in a NOD/SCID mouse model. (2001) (25)
- Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study (2018) (25)
- Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers (2012) (25)
- Vasculogenic potential of long term repopulating cord blood progenitors (2004) (24)
- Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction (2001) (24)
- TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers (2019) (23)
- Interleukin-3 in vivo: kinetic of response of target cells. (1993) (23)
- Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. (2019) (23)
- Opposite effect of tumor necrosis factor alpha on granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor-dependent growth of normal and leukemic hemopoietic progenitors. (1990) (23)
- The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma (2015) (23)
- Essential thrombocythemia: impaired regulation of megakaryocyte progenitors. (1991) (23)
- Peripheral blood stem cells in acute myeloid leukemia: biology and clinical applications. (1996) (22)
- Anticoagulation for central venous catheters in patients with cancer. (2014) (22)
- In vivo effect of granulocyte-macrophage colony-stimulating factor on the kinetics of human acute myeloid leukemia cells. (1991) (21)
- Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin’s lymphoma: a case report and review of the literature (2014) (21)
- A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience (2018) (21)
- DISAPPEARANCE OF PHILADELPHIA CHROMOSOME AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR TREATMENT OF CHRONIC MYELOID LEUKAEMIA IN ACUTE CRISIS (1982) (21)
- Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. (2019) (21)
- Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy (2004) (21)
- Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II) (2019) (21)
- Melanoma Brain Metastases in the Era of Target Therapies: An Overview (2020) (20)
- Thrombocytopenia in acute leukaemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors (1991) (20)
- Role of interferon in melanoma: old hopes and new perspectives (2017) (20)
- Front‐line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group (2017) (20)
- BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody (2018) (20)
- In-vitro effect of retinoic acid on normal and chronic myeloid leukemia granulopoiesis. (1985) (20)
- An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient. (2009) (20)
- ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells (2003) (20)
- Granulocyte‐Macrophage colony stimulating factor and interleukin 3: Target cells and kinetics of response in vivo (1993) (20)
- Cytokine receptors, growth factors and cell cycle in human bone marrow and peripheral blood hematopoietic progenitors. (1997) (19)
- High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma. (1993) (19)
- Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine (2019) (19)
- Potential of afatinib in the treatment of patients with HER2-positive breast cancer. (2012) (19)
- Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy. (2018) (19)
- Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. (2011) (18)
- Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas (2012) (18)
- Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective (2014) (18)
- Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients (2012) (18)
- Breast Cancer Research and Treatment (2004) (18)
- Differential effect of transforming growth factor beta 1 on the proliferation of human lymphoid and myeloid leukemia cells. (1991) (18)
- Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors. (2014) (18)
- Ex Vivo Expansion of Cord Blood Progenitors (1998) (18)
- Emerging molecular target antagonists for the treatment of biliary tract cancer (2018) (17)
- Refreezing of cord blood hematopoietic stem cells for allogenic transplantation: in vitro and in vivo validation of a clinical phase I/II protocol in European and Italian Good Manufacturing Practice conditions. (2008) (17)
- TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study (2021) (17)
- Jaw complications in breast and prostate cancer patients treated with zoledronic acid (2006) (17)
- Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: Consensus of an Italian expert panel (2011) (17)
- Aromatase inhibitors as adjuvant therapy for breast cancer. (2009) (17)
- Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. (2020) (17)
- Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice (2017) (16)
- Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses (2019) (16)
- In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy (2012) (16)
- Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. (2007) (16)
- Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison (2010) (16)
- In vivo priming of human normal neutrophils by granulocyte‐macrophage colony stimulating factor: effect on the production of platelet activating factor (1990) (16)
- Megakaryocyte growth and development factor (MGDF)-induced acute leukemia cell proliferation and clonal growth is associated with functional c-mpl (1997) (16)
- Rationale for the use of granulocyte-macrophage colony-stimulating factor in oncology. (1994) (16)
- Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma (2016) (16)
- A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. (2012) (15)
- CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes (2020) (15)
- Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial. (2008) (15)
- Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer (2016) (15)
- Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity (2016) (14)
- Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. (2020) (14)
- A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients (2015) (14)
- Granulocyte-macrophage colony-stimulating factor and myelodysplastic syndromes. (1988) (14)
- The role of c‐Mpl ligands in the expansion of cord blood hematopoietic progenitors (1998) (14)
- Flow cytometric detection and quantitative analysis of the GM-CSF receptor in human granulocytes and comparison with the radioligand binding assay. (1996) (14)
- Expression of HLA class II (DR, DQ) determinants by normal and chronic myeloid leukemia granulocyte/monocyte progenitors. (1986) (14)
- Autologous bone marrow transplantation in acute leukemia. (1987) (14)
- Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. (2013) (14)
- Alpha–fetoprotein elevation in NUT midline carcinoma: a case report (2017) (14)
- Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update. (2019) (14)
- Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP). (2013) (14)
- Gastrointestinal Stromal Tumors: Should They Be Treated with the Same Systemic Chemotherapy as Other Soft Tissue Sarcomas? (2003) (14)
- Melanoma and other skin tumors (2012) (13)
- ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment. (2012) (13)
- Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukaemia in chronic phase: a comparison of transplant versus no‐transplant in a cohort of 258 patients first seen in Italy between 1984 and 1986 (1993) (13)
- Role of trastuzumab in the management of HER2-positive metastatic breast cancer. (2010) (13)
- Blood cell redistribution in the lung after administration of recombinant human granulocyte-macrophage colony-stimulating factor. (1995) (13)
- Retinoic acid enhances the growth of only one subpopulation of granulomonocyte precursors. (1984) (13)
- Short term treatment with Escheria coli recombinant human granulocyte‐macrophage–colony stimulating factor prior to chemotherapy for Hodgkin disease (2000) (13)
- Role of different medium and growth factors on placental blood stem cell expansion: an in vitro and in vivo study (2002) (13)
- Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP). (2013) (12)
- Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma (2018) (12)
- The involvement of human-nuc gene in polyploidization of K562 cell line. (2000) (12)
- Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy. (2014) (12)
- Efficient Transcriptional Targeting of Human Hematopoietic Stem Cells and Blood Cell Lineages by Lentiviral Vectors Containing the Regulatory Element of the Wiskott‐Aldrich Syndrome Gene (2009) (12)
- Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights (2020) (12)
- Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART) (2013) (12)
- PF586 SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY (2019) (12)
- Phase IB/II study of the HSP90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer. (2012) (11)
- Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update. (2021) (11)
- 484PDAnalysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142 (2017) (11)
- Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR (2018) (11)
- Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification). (2013) (11)
- Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. (2015) (11)
- Feasibility of cord blood stem cell manipulation with high-energy shock waves: an in vitro and in vivo study. (2005) (11)
- Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. (2017) (11)
- Adoptive immunotherapy against sarcomas (2015) (11)
- Sustained Long‐Term Engraftment and Transgene Expression of Peripheral Blood CD34+ Cells Transduced with Third‐Generation Lentiviral Vectors (2008) (11)
- Drug-mediated marrow purging: mafosfamide in adult acute leukemia in remission. The experience of the Italian study group. (1989) (11)
- Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients. (2013) (10)
- Allogeneic hemopoietic stem cell transplantation in solid tumors. (2005) (10)
- Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line (2016) (10)
- Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? (2019) (10)
- Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study (2008) (10)
- Treatment of metastatic melanoma: a multidisciplinary approach. (2017) (10)
- Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. (2019) (9)
- Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models (2014) (9)
- Androgen receptor status predicts development of brain metastases in ovarian cancers (2017) (9)
- Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival. (2004) (9)
- Phase II Trial of Panitumumab in Combination with Oxaliplatin and Capecitabine Chemotherapy as 1st Line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases: The Metapan Study (2012) (9)
- Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. (2019) (9)
- PALETTE : Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients (2012) (9)
- Trastuzumab beyond disease progression: case closed? (2009) (9)
- In vivo effect of human granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil GM-CSF receptors. (1995) (9)
- Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (2012) (9)
- Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab (2008) (8)
- [Prevention and treatment of febrile neutropenia]. (1997) (8)
- Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives (2019) (8)
- Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells (2015) (8)
- Serial Transplantations in Nonobese Diabetic/Severe Combined Immunodeficiency Mice of Transduced Human CD34+ Cord Blood Cells: Efficient Oncoretroviral Gene Transfer and Ex Vivo Expansion Under Serum‐Free Conditions (2006) (8)
- Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-lnduced Killer Cells (2017) (8)
- Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program. (2019) (8)
- MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors. (2002) (8)
- Dose-dense Vinorelbine and Paclitaxel with Granulocyte Colony-stimulating Factor in Metastatic Breast Cancer Patients: Anti-tumor Activity and Peripheral Blood Progenitor Cell Mobilization Capability (2003) (8)
- Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours. (2007) (8)
- High-risk osteosarcoma (OS): Preliminary results of the ISG-SSG II protocol (2005) (8)
- Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer (2010) (8)
- Abstract 2603: Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab + ipilimumab in CheckMate-142 (2018) (7)
- Gingival metastasis of a radiotherapy-induced breast angiosarcoma: diagnosis and multidisciplinary treatment achieving a prolonged complete remission. (2012) (7)
- Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. (2021) (7)
- Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients (Cancer (2009) 115, (2980-2987)) (2009) (7)
- CSFs, from basic science to clinical trials. (1989) (7)
- Erythrocyte macrocytosis is a rather common, apparently uneventful yet unexplained finding in GIST imatinib (I) chronic therapy (2005) (7)
- A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient (2021) (7)
- Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study. (2017) (7)
- A phase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naive metastatic pancreatic cancer. (2010) (7)
- Trastuzumab treatment in breast cancer. (2006) (7)
- Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? (2011) (7)
- Differences in the in vitro growth pattern of fresh and cryopreserved granulo-monopoietic precursors. (1984) (7)
- Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures (2020) (7)
- Post-Transplant Cyclophosphamide and Tacrolimus—Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors (2021) (7)
- Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO (2022) (7)
- Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: a retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer. (2016) (7)
- Ex vivo expansion of megakaryocytes. (2000) (7)
- Activation of JAK 2 in Human Vascular Endothelial Cells by Granulocyte-Macrophage Colony-Stimulating Factor (1997) (7)
- Controversies in breast cancer: adjuvant and neoadjuvant therapy (2005) (6)
- Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective (2021) (6)
- Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report (2016) (6)
- Acute pulmonary failure after the first administration of recombinant human granulocyte-macrophage colony-stimulating factor. (1992) (6)
- Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors. (2006) (6)
- A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab. (2015) (6)
- Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients (2021) (6)
- GM-CSF: intravenous versus subcutaneous treatment. (1990) (6)
- Veliparib: a new therapeutic option in ovarian cancer? (2019) (6)
- Regression of metastatic osteosarcoma following non-myeloablative stem cell transplantation. A case report. (2003) (6)
- Double Autologous Transplant Versus Tandem Autologus - Non Myeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma. (2005) (6)
- [Diagnostic approach to the anemic cancer patient]. (1997) (6)
- Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index (2021) (6)
- High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. (2000) (6)
- Expression of HLA class II determinants by normal and chronic myeloid leukemia progenitors. (1987) (6)
- Trisomy 8 and an unbalanced t(5;17)(q11;p11) characterize two karyotypically independent clones in a case of idiopathic myelofibrosis evolving to acute nonlymphoid leukemia. (1991) (6)
- Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study) (2019) (6)
- Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives (2015) (6)
- Effects of Human FLT 3 Ligand on Myeloid Leukemia Cell Growth : Heterogeneity in Response and Synergy With Other Hematopoietic Growth Factors (2000) (6)
- Concurrent Radiotherapy Does Not Affect Adjuvant CMF Delivery but is Associated with Increased Toxicity in Women with Early Breast Cancer (2006) (6)
- Preliminary analysis of a phase II, multicenter, randomized, active-control study to evaluate the efficacy and safety of eganelisib (IPI 549) in combination with nivolumab compared to nivolumab monotherapy in patients with advanced urothelial carcinoma. (2021) (5)
- A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III) (2021) (5)
- Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma. (2007) (5)
- Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer (2017) (5)
- Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study (2020) (5)
- Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers (2020) (5)
- Involvement of a serine protease in the synthesis of platelet-activating factor by endothelial cells stimulated by tumor necrosis factor-alpha or interleukin-1 alpha. (1994) (5)
- Treating breast cancer with cell-based approaches: an overview (2017) (5)
- MYELOFIBROSIS AND PROSTAGLANDINS: EFFECT OF PROSTAGLANDIN E1 ON COLONY‐FORMING CELLS (CFU‐GM) (1981) (5)
- High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients (2021) (5)
- In vitro reappearance of myeloid progenitors killed by mafosfamide. (1987) (5)
- Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP). (2013) (5)
- Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation. (2018) (5)
- Comparison of endorectal magnetic resonance imaging, clinical prognostic factors and nomograms in the local staging of prostate cancer patients treated with radiotherapy. (2008) (5)
- Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. (2021) (5)
- The relevance of cell kinetics for optimal scheduling of 1-β-d-Arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML) (2004) (5)
- A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): An Italian Sarcoma Group (ISG) study. (2016) (5)
- Rationale for the use of metronomic chemotherapy in gastrointestinal cancer (2018) (5)
- Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial (2021) (5)
- Targeted agents: how can we improve the outcome in biliary tract cancer? (2013) (4)
- Normal and leukaemic granulopoiesis. (1981) (4)
- Effect of recombinant human IL-3 on the mitotic index and karyotype of hemopoietic cells. (1991) (4)
- Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients (2019) (4)
- Human GM-CSF in vivo: identification of the target cells and of their kinetics of response. (1990) (4)
- A nonrandomized phase II trial of sorafenib (S) and everolimus (E) in unresectable metastatic osteosarcoma (OST) patients (pts) relapsed after standard chemotherapy. (2014) (4)
- Final toxicity results of a phase I dose-escalation trial of tremelimumab (CP-675206) in combination with gemcitabine in chemotherapy-naive patients (pts) with metastatic pancreatic cancer. (2011) (4)
- Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience (2019) (4)
- "Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer. (2019) (4)
- Comparison of Endorectal Magnetic Resonance Imaging, Clinical Prognostic Factors and Nomograms in the Local Staging of Prostate Cancer Patients Treated with Radiotherapy (2008) (4)
- Effect of Hemopoietic Growth Factors on the Proliferation of Acute Myeloid and Lymphoid Leukemias. (1990) (4)
- [Prevalence of anemia in oncologic patients treated with chemotherapy. Italian survey at the national level]. (2001) (4)
- Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016. (2019) (4)
- OA07.07 Quality of Life (QoL) Analysis in Lung Cancer: A Systematic Review of Phase III Trials Published Between 2012 and 2018 (2019) (4)
- An in vitro study of basophil production in chronic myeloproliferative disorders. (1984) (4)
- A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy. (1995) (4)
- HER2 and central nervous system metastasis in patients with breast cancer. (2004) (4)
- Improvement of metastatic colorectal cancer patient survival: Single institution experience. (2018) (4)
- 2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab) (2015) (4)
- Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors (2022) (4)
- Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: The value of early evaluation of the course of the disease (2005) (4)
- Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer (2020) (4)
- Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. (2021) (4)
- MACOP-B for advanced stage large cell lymphoma (DLCL). More is better? Italian Multiregional Cooperative Study Group (IMCSGL). (1991) (3)
- What can we learn from the ZOOM trial?--Authors' reply. (2013) (3)
- [The use of erythropoietin alpha in programs of high-dose chemotherapy]. (2000) (3)
- Bone metastases in biliary cancers: A multicenter retrospective survey (2018) (3)
- Preventing Venous Thromboembolism in Patients with Cancer. (2019) (3)
- Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma (2022) (3)
- Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma (2022) (3)
- Tumor progression in osteosarcoma (OS): Role of the chemokine receptor CXCR4 and of its ligand stromal-cell derived factor 1 (SDF-1). (2004) (3)
- BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report (2017) (3)
- Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks (2011) (3)
- A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study. (2015) (3)
- Duration of trastuzumab for HER2-positive breast cancer. (2013) (3)
- Prognostic factors in unresectable biliary tract cancer: a GICO (Gruppo Italiano COlangiocarcinoma) retrospective analysis. (2017) (3)
- A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL (2007) (3)
- EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma (2021) (3)
- Non-linear relationship between HER-2 expression and response to trastuzumab in breast cancer cells. (2006) (3)
- Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy. (2014) (3)
- Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP) (2013) (3)
- DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination (2022) (3)
- Activity of cytokine-induced killer cells against bone and soft tissue sarcoma (2014) (3)
- Oncology in the nineties: from genes to therapy. (1991) (3)
- Prospective evaluation of the cardiovascular safety profile of abiraterone acetate (AA) in mCRPC patients (pts). (2016) (3)
- Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy (2015) (3)
- Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature. (2012) (3)
- A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy (2021) (3)
- Abstract PD10-07: Hormone-Receptor Expression and Activity of Trastuzumab-Based Therapy in HER2-Positive Advanced Breast Cancer Patients (2010) (2)
- Abstract P1-08-23: Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer (2013) (2)
- Somatic mutations of EGFR signal transducers and expression of tumor suppressor PTEN in biliary tract carcinoma (2007) (2)
- D26Pertuzumab and trastuzumab-emtansine in HER2 positive metastatic colorectal cancer: the HERACLES B TRIAL (2016) (2)
- Responsiveness to prostaglandin E1 of different subtypes of normal and pathological committed granulomonopoietic precursors. (1983) (2)
- Increase of creatine kinase value (CK) correlates with muscoloskeletal complaints (MSC) in GIST patients during imatinib therapy. (2006) (2)
- Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial (2020) (2)
- Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis (2021) (2)
- Imatinib mesylate (IM) therapy in elderly patients affected by advanced gastrointestinal stromal tumor (GIST). (2011) (2)
- Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018. (2019) (2)
- LIMITED GRAFT-VERSUS MYELOMA EFFECT AFTER LOW-DOSE TBI BASED NON-MYELOABLATIVE ALLOGRAFTING EMPLOYED AS SALVAGE TREATMENT COMPARED TO FIRST LINE TREATMENT (2006) (2)
- Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients (2021) (2)
- An update of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. (2007) (2)
- Adjuvant chemotherapy following curative intent hepatectomy for intrahepatic cholangiocarcinoma: Results from a multi-institutional analysis of 575 patients. (2012) (2)
- A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma (CS) expressing platelet-derived growth factor receptor-{alpha} or -{beta} (PDGFR-{alpha}/PDGFR-{beta}): An Italian Sarcoma Group study. (2010) (2)
- 3*A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab (2015) (2)
- Response to Eribulin in a patient with metastatic uterine leiomyosarcoma: a case report. (2020) (2)
- Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC) (2012) (2)
- Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer? (2007) (2)
- Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy) (2021) (2)
- Positive and negative signals in the control of myelopoiesis. (1989) (2)
- The release of platelet-activating factor during phagocytosis by polymorphonuclear neutrophils and monocytes. (1982) (2)
- Autologous bone marrow transplantation and pharmacological bone marrow purging: in vitro use of maphosphamide and bleomycin. (1988) (2)
- Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis. (2020) (2)
- Preclinical activity of lenalidomide in metastatic colorectal cancer. (2013) (2)
- Effect of high doses of cytostatic drugs on cell kinetics of the acute myeloid leukemia of the BN rat and of human AML (1979) (2)
- Patient self-evaluation of side-effects related to adjuvant chemotherapy in breast cancer: A prospective study. (2015) (2)
- Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy (2021) (2)
- Correlation of 11C-choline PET and PSA values in patients with prostate cancer and biochemical relapse after primary treatments (2007) (2)
- Atypical myeloproliferative disorder associated with a 21 trisomic clone (1981) (1)
- The 41st Annual Meeting of The American Society of Clinical Oncology (2005) (1)
- 1074P Italian nivolumab Expanded Access Program (EAP) in melanoma adjuvant setting: Patients outcomes and safety profile (2021) (1)
- Vascular Endothelial Growth Factor and Its Receptor KDR/flk-1 Play Important Roles in Hematopoiesis. (2001) (1)
- Autologous Bone Marrow Transplantation in Acute Lymphoblastic Leukemia—Mafosfamide Italian Study Group (1988) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Abstract 5551: Antitumor activity, gene and miRNA modulation upon ET-743 treatment in an intrahepatic cholangiocarcinoma patient-derived xenograft model (2014) (1)
- Trastuzumab in the adjuvant setting: A practical review (2011) (1)
- CFU-C and prognosis in a case of posthepatitic aplastic anaemia. (1978) (1)
- Global differences in chemotherapeutic regimens of soft tissue sarcoma (STS): Results of PALETTE, an EORTC 62072/GSK VEG110727 global network phase III trial of pazopanib versus placebo. (2012) (1)
- 448P Predictive factor of cardiotoxicity in fluoropyrimidine-treated colorectal cancer patients: Interim analysis of the prospective observational CHECKPOINT trial (2020) (1)
- Effect of AZD0530 (saracatinib) on biliary cancer cell motility and invasion. (2011) (1)
- Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells (2015) (1)
- Imaging tumor response to therapy (2012) (1)
- Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation (2016) (1)
- Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models (2021) (1)
- Prostaglandins and myelopoiesis: effect of prostaglandin E1 on normal and chronic myeloid leukemia colony forming cells (CFU-GM) subpopulations. (1981) (1)
- Human gamma interferon modifies C-myc expression and growth pattern of U937 cell line but not of its subclone 1937 (1986) (1)
- 1131 POSTER Osteonecrosis of the jaw (ONJ) in patients treated with Bisphosphonates (BP): the experience of the "Rete Oncologica di Piemonte e Valle D'Aosta" (North-Western Italy) (2007) (1)
- Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: Preliminary data from the prospective observational CHECKPOINT trial (NCT02665312) (2019) (1)
- Postoperative nomogram for predicting survival after resection for intrahepatic cholangiocarcinoma. (2013) (1)
- Anthracycline-based adjuvant chemotherapy in breast cancer (2010) (1)
- A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo. (2007) (1)
- Antiproliferative effect of mTOR inhibitor everolimus (EV) alone or in combination with multikinase inhibitor (MK-I) sorafenib (SOR) in preclinical models of osteosarcoma (OS). (2010) (1)
- Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities. (2011) (1)
- Mafosfamide and bleomycin purging effects on normal marrow and K562 cells (1986) (1)
- Tandem transplant with autografting followed by non-myeloablative allografting for treatment of multiple myeloma: an Italian multi center trial (2003) (1)
- 70MO Genomic profiling to expand precision cancer medicine in the real world: The ROME trial (2023) (1)
- Tumor control with palliative external beam radiation therapy (EBRT) in advanced and unresectable osteosarcoma (OS) progressing after standard treatment. (2019) (1)
- Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for breast cancer with > 9 positive nodes: 15-year results from the Italian registry (2008) (1)
- Target cells for GM-CSF and kinetics of response. (1990) (1)
- Outcome of patients with HER2+ advanced breast cancer (ABC) progressing during trastuzumab (T)-based treatment (2005) (1)
- Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme (2014) (1)
- Positron-emission tomography in cancer therapy. (2006) (1)
- Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST (2022) (1)
- Phase II study of 153-samarium-EDTMP followed by haematopoietic stem cell for patients with osteosarcoma with bone metastasis. (2011) (1)
- Colony stimulating activity (CSA) in human adult and cord blood. Interaction between leucocytes and plasma. (1980) (1)
- A risk-based individualized follow-up after complete surgery as an effective procedure to reduce the relapse (R) impact in GIST patients (pts). (2013) (1)
- Effect of lithium on normal and chronic granulocytic leukemia colony forming cells (CFU-GM) (1981) (1)
- Abstract C213: Sorafenib blocks tumor growth, angiogenesis, and metastatic potential in preclinical models of osteosarcoma through the inhibition of ERK1/2, MCL‐1, and ezrin pathways (2009) (1)
- MIC A/B Protein Expression Associates with Trastuzumab-Resistant Breast Cancer Cells Leading to Effective Immunotherapy by Cytokine Induced Killer Cells. (2009) (1)
- Modulation by retinoic acid of the growth of bone marrow cell progenitors from patients with myelodysplastic syndrome. (1989) (1)
- The Tyrosine Kinase c-Met Is Selectively Expressed on Motile Hematopoietic Progenitors Following G-CSF Administration and Promotes Mobilization by Regulating Stem Cell Niche Components. (2006) (1)
- Megakaryocyte differentiation and reconstitution in nod/scid mice of CD34+ cord blood cells after extensive ex vivo expansion (2000) (1)
- Hypertension monitoring as a tool to predict congestive heart failure (CHF) during sunitinib (SU) therapy in GIST and renal cell carcinoma (RCC). (2011) (1)
- Abstract P6-10-09: Mutational landscape of breast cancer patients in ROME trial: preliminary results (2023) (1)
- 1633P Explorative model of imatinib resistant wild type GIST and potential immunotherapy strategies (2020) (0)
- Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies (2017) (0)
- Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort (2014) (0)
- Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study (2022) (0)
- A09Self-evaluation subjective toxicity according to the Common Toxicity Criteria in breast cancer patients undergoing adjuvant chemotherapy: final results of an Italian prospective study (2015) (0)
- Biases in assessment and reporting of health-related quality of life (QoL): A systematic review of oncology randomized phase III trials published between 2012 and 2016. (2018) (0)
- Prognostic Implication of Somatic Mutations by Next Generation Sequencing: an Analysis from the MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma Patients (2016) (0)
- Subject Index Vol. 69, 1983 (1983) (0)
- ONE-HUNDRED-EIGHT CONSECUTIVE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THE TANDEM AUTO-TBI BASED MINI-ALLO APPROCH (2006) (0)
- H2 receptor antagonists and human granulopoiesis (1985) (0)
- Impact of the pandemic on surgical oncology in Piedmont, Italy: a retrospective observational study (2022) (0)
- H15Rare epidermal growth factor receptor (EGFR) mutations in a 425 patients population with non-small cell lung cancer (NSCLC): clinical, molecular and survival data. The IRCCS Candiolo experience (2015) (0)
- Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference (2007) (0)
- 14 The status of bone marrow transplant clinical trials (2003) (0)
- [GM-CSF: target cells and their response kinetics]. (1989) (0)
- Abstract 3591: CSPG4 as innovative target for CAR redirected CIK lymphocytes against soft tissue sarcomas (2018) (0)
- Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy (2022) (0)
- Hemopoietic growth factor-independent TGFβ1 inhibition of human acute myeloid leukemia cell growth (1995) (0)
- TANDEM AUTO-MINI ALLO APPROACH FOR NEWLY DIAGONSED MULTIPLE MYELOMA: AN UPDATE OF THE ITALIAN EXPERIENCE (2005) (0)
- Interleukin 1 induces biosynthesis of platelet activating factor in human endothelial cells by deacylation/reacetylation process (1987) (0)
- Preoperative Tru-Cut biopsy (POB) for the diagnosis of retroperitoneal soft tissue sarcomas (RPS) and risk of local recurrence (LR) compared to primary surgery of the tumor. (2017) (0)
- Efficacy and Safety of Ipilimumab Reinduction Therapy Patients with Pretreated Advanced Melanoma Participating in an Expanded Access Programme (EAP) in Italy (2012) (0)
- Antitumor activity of sorafenib in osteosarcoma (OS) preclinical models (2008) (0)
- Induction of differentiation: a possible therapeutic approach to the treatment of hematologic malignancy (1987) (0)
- 763P Treatment response to non-platinum therapies in ovarian cancer patients according to BRCA status: A retrospective analysis of a large multicentric cohort (2021) (0)
- Activation of immune response in refractory patients to standard treatment (T.R.A.N.S.L.A.T.E.) (2018) (0)
- Underuse of anthracyclines in women with HER2-positive advanced breast cancer. (2010) (0)
- Risk of adverse cardiovascular events (CVE) and incident diabetes mellitus (DM) in patients (pts) with prostate cancer (PC) treated with androgen deprivation therapy (ADT): A meta-analysis of adjusted observational results. (2012) (0)
- Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukocyte antigen barriers (2022) (0)
- 164. Effect of recombinant human stem cell factor on the proliferation and differentiation in vitro of hemopoietic progenitors in myeiodisplastic syndromes (1992) (0)
- Autoimmune Hepatitis - Overlap Syndrome (AH) occurring during imatinib therapy in a gastro-intestinal stromal tumor (GIST) patient. (2004) (0)
- The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma (2015) (0)
- Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model (2022) (0)
- LEUCEMIA MIELOIDE CRONICA (Sindromi Mieloproliferative Crioniche) (2000) (0)
- INCIDENCE OF INVASIVE ASPERGILLOSIS IN ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS: AN ITALIAN PROSPECTIVE MULTICENTER STUDY (2004) (0)
- PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models (2017) (0)
- Abstract A82: HHER2‐positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and become sensitive to the multitargeted kinase inhibitor sorafenib (2009) (0)
- Diagnostic accuracy of portal-phase CT and MRI with mangafodipir trisodium in detecting liver metastases from colorectal carcinoma (2006) (0)
- Abstract 3234: PD-1 is intrinsically expressed by lung cancer cells with stemness features inhibited by PD-1 blockade (2019) (0)
- Metastases outside the abdomen (MOA) are associated with initial high tumor burden (TB) in gastrointestinal stromal tumors (GIST). (2006) (0)
- Invasive aspergillosis in allogeneic stem cell recipients: what are we doing? An Italian prospective study (2008) (0)
- Role of prostaglandin E (PGE) in the regulation of normal and chronic myeloid leukemia (CML) granulopoiesis (1980) (0)
- Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours (2019) (0)
- G1* PRIMARY CHEMORADIATION WITH FOLFOX-4 AND CETUXIMAB IN LOCALLY ADVANCED ESOPHAGEAL CANCER: PRELIMINARY DATA FROM B152 TRIAL (2008) (0)
- Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: Retrospective analysis of clinical outcomes. (2020) (0)
- AUTOGRAFTING FOLLOWED BY LOW DOSE TBI BASED NON MYELOABLATIVE ALLOGRAFTING IN MULTIPLE MYELOMA: THE GITMO EXPERIENCE (2003) (0)
- To the editor [15] (2006) (0)
- TROMBOCITEMIA ESSENZIALE (Sindromi Mieloproliferative Croniche) (2000) (0)
- High-grade soft tissue sarcomas (STS) of elderly (>=70 years) patients (E-STS): Feasibility and morbidity of anthracycline-based chemotherapy (A-CT) in a selected subset of patients. (2010) (0)
- P1-18-02: Descriptive Analysis of the Management of Breast Cancer Patients with a Solitary Lesion Diagnosed with 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan. (2011) (0)
- INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line (2023) (0)
- Use of FDG-PET (PET) to select patients for metastasectomy for high-grade soft tissue sarcomas (HG-STS) (2008) (0)
- Survival of metastatic colorectal cancer patients at Candiolo Cancer Institute. (2017) (0)
- Antitumor activity of pazopanib (P) and trametinib (T) in preclinical models of osteosarcoma (OS). (2019) (0)
- 65P Prognostic role of PECS2 index in advanced biliary tract cancer (BTC) patients treated with first line chemotherapy: Training and validation cohorts (2020) (0)
- Sustained Long Term Engraftment and Transgene Expression of Peripheral Blood CD34+ Cells Transduced with Advanced Lentiviral Vectors in the Preence of ABC Inhibitors. (2004) (0)
- Cardiac metastasis arisen from a limb grade 1 mixoid liposarcoma six years after its radical resection (2005) (0)
- Microenvironment and Immunology Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue (2013) (0)
- Alpha–fetoprotein elevation in NUT midline carcinoma: a case report (2017) (0)
- 350 Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitors Potentiate Trabectedin Activity in Preclinical Models of Bone and Soft Tissue Sarcomas (2012) (0)
- Low doses of ketoconazole and prednisone in patients with castration resistant prostate cancer (CRPC): A retrospective study on 73 patients. (2013) (0)
- Chronic and late-onset toxicities from immune checkpoints inhibitors (ICIs): Analysis of the publications leading to ICIs approval between 2011 and 2019 (2019) (0)
- Hypertension and cardiotoxicity in metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU). (2012) (0)
- Targeting The MTOR Pathway In Malignant Pleural Mesothelioma (2011) (0)
- PD-006Gemcitabine and Oxaliplatin (GEMOX) with or without Panitumumab as First-Line Treatment in Advanced Biliary Tract Cancer; final results and subgroup analysis of the Vecti-BIL Study (2015) (0)
- Impact of upfront multidisciplinary tumor board (MTB) evaluation on breast sarcoma (BS) outcome. (2020) (0)
- A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index (2021) (0)
- Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin’s lymphoma: a case report and review of the literature (2014) (0)
- Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT) (2022) (0)
- Related articles (2013) (0)
- Contents Vol. 69, 1983 (1983) (0)
- Effects of prostaglandin E1 (PGE1) on colony forming cells (CFU-GM) subpopulations from normal subjects and from patients with chronic myeloproliferative disorders (1981) (0)
- Reply to A. Sánchez-Muñoz et al (2009) (0)
- Migration of neutrophils to the oral mucosa during treatment with recombinant human Granulocyte Macrophage Colony Stimulating Factor. (1992) (0)
- Abstract LB-366: Everolimus (EV) potentiates Sorafenib (SOR)activity in osteosarcoma (OS) preclinical models: a combination targeting the crosstalk between ERK1/2 and mTORC1/2 signaling pathways (2012) (0)
- The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer. (2016) (0)
- Abstract 569: Expression and modulation by IFN of HLA class I APM components in melanoma: Potential biomarkers of clinical response to checkpoint inhibitors (2019) (0)
- Preclinical evidence of ET-743 as a potential chemotherapy option for the treatment of biliary carcinoma. (2013) (0)
- Translocation of the c-myc oncogene 3′ to the immunoglobin heavy chain enhancer in the tumor DNA from a Burkitt lymphoma (1986) (0)
- Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients (2021) (0)
- 134 Dissecting the mTOR pathway in osteosarcoma (2010) (0)
- Disease and Comorbidity Status Predict Outcome after Nonmyeloablative Allografting for Advanced Haematological Malignancies. (2007) (0)
- Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) Reduces Pancytopenia After Rescue Therapy in a Patient with Hodgkin's Lymphoma. (1990) (0)
- Concomitant radiation therapy does not affect adjuvant CMF delivery in patients with operable breast cancer. (2004) (0)
- Blood c cell rredistribution iin tthe llung a after a administration of rrecombinant h human g granulocyte-macrophage colony-stimulating ffactor (1995) (0)
- INCIDENCE OF HHV-6 AFTER NONMYELOABLATIVE HSCT IN REFRACTORY MALIGNANCIES (2007) (0)
- 602 Is There a Role for Allografting in Myeloma in the Era of New Drugs?: Long-Term Follow-Up of a Comparative Study (2011) (0)
- Expanded Human NKT Type II Cells: Effective Against Colon Cancer Cells, Safe across Major MHC Barriers and Successfully Expandable after Non-Myeloablative HCT for Solid Tumors. (2005) (0)
- 45th Annual Meeting of the Italian Cancer Society Bergamo, 9-12 November 2003 (2004) (0)
- Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect. (2018) (0)
- Lentiviral Engineered T Regulatory Cells Effectively Inhibit Lymphocytes Alloreactivity across Major HLA Barriers (2008) (0)
- Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models (2014) (0)
- Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in KRAS wild-type Advanced Biliary Tract Cancer : a randomized , Phase II trial ( Vecti-BIL Study ) Running title GEMOX and Panitumumab in wt KRAS BTC (2016) (0)
- Human Endothelial Cells Produce Platelet Activating Factor in Response to Interleukin 1 (1987) (0)
- Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab. (2016) (0)
- Phase II trial of induction GEMOX followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. (2016) (0)
- Abstract 3709: PARP1 expression (PARP1expr) drives synergy between PARP1 inhibitors (PARP1-Is) and trabectedin (TR) (2016) (0)
- D28The FUNNEL: a precision medicine project for metastatic colorectal cancer (2016) (0)
- Efficacy of low-dose ketoconazole in the treatment of castration-resistant prostate cancer (CRPC): A single-institution experience. (2012) (0)
- Different Kinetic Pattern of Chronic Myeloid Leukemia: Lymphoblastic and Myeloblastic Blastic Crisis 1 (1980) (0)
- Tandem autografting-nonmyeloablative allografting for newly diagnosed multiple myeloma: The GITMO (gruppo italiano trapianto midollo osseo) experience (2007) (0)
- 000379 CONCURRENT RADIOTHERAPY DOES NOT IMPAIR OPTIMAL DELIVERY OF ADJUVANT CMF CHEMOTHERAPY BUT INCREASES TOXICITY IN EARLY BREAST CANCER PATIENTS (2005) (0)
- Cytokines performance during nivolumab treatment: A subgroup analysis of NIVACTOR study. (2021) (0)
- HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis (2022) (0)
- C-reactive protein (CRP) and peripheral blood monocyte count (PBMC) in patients (pts) with advanced soft tissue sarcomas (ASTS) treated with trabectedin (TR): correlation with progression-free survival (PFS). (2015) (0)
- HSCT With Mismatch Unrelated Donor: A Comparison of ATG vs. PT-Cy-Based GvHD Prophylaxis in Pediatric and Adult Patients (2020) (0)
- LOW-DOSE TBI-BASED NON-MYELOABLATIVE ALLOGRAFTING IN NEWLY DIAGNOSED MULTIPLE MYELOMA (2004) (0)
- NONMYELOABLATIVE ALLOGRAFTING OR AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (2007) (0)
- Immunological and Genetic Biomarkers of Sarcomas (2019) (0)
- Cytokineinducedkillercells asadoptiveimmunotherapy strategytoaugmentgraftversus tumorafterhematopoieticcell transplantation (2009) (0)
- 7q-and loss of a polymorphism for the met oncogene in a patient with myelofibrosis (1987) (0)
- the Amplification and Self-Renewal of Repopulating Stem Cells of Human CD34+ Cord Blood Cells After Ex Vivo Expansion: Evidence for Engraftment in Nonobese Diabetic Severe Combined Immunodeficient Mice (2013) (0)
- Contents Vol. 68, 2005 (2005) (0)
- Allogeneic hematopoietic cell transplantation after reduced intense conditioning as adoptive cell therapy in resistant metastatic colorectal carcinoma. The European experience. (2006) (0)
- Effect of interferon-gamma on HLA class II antigen expression and sensitivity to prostaglandin E1 by normal and leukemic myeloid progenitors. (1988) (0)
- Autoimmune Hepatitis - Overlap Syndrome (AH) occurring during imatinib therapy in a gastro-intestinal stromal tumor (GIST) patient (2004) (0)
- Efficient Oncoretroviral Gene Transfer in Primary, Secondary and Tertiary NOD/SCID Mice under Serum-Free Conditions. (2004) (0)
- Subject Index Vol. 68, 2005 (2005) (0)
- Corrigendum to ""Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer" [Crit. Rev. Oncol. Hematol. 133 (January) (2019) 17-24]. (2020) (0)
- Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy (2023) (0)
- Selected Highlights from the 26th San Antonio Breast Cancer Symposium (2004) (0)
- PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study (2021) (0)
- newer imaging techniques that are sensitive to tumor biology open the way to exciting developments in this field (2012) (0)
- E28Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy (2015) (0)
- Abstract LB-042: Xenopatients help in redefining medical therapeutic algorithms in high risk ovarian cancer (2016) (0)
- P2-12-31: Moderate Immunohistochemical Expression of HER2 (2+) without HER2 Gene-Amplification Is a Negative Prognostic Factor in Early Breast Cancer. (2011) (0)
- Abstract 885: Anti-CSPG4 CAR.CIK lymphocytes are effective against advanced sarcomas in 3D spheroid and xenograft models (2020) (0)
- hematopoietic progenitor cells via ROS signaling induced mobilization of - Enhanced c-Met activity promotes G-CSF (2011) (0)
- Low dose TBI based non myeloablative allografting for advanced hematological malignancies: A multicenter experience. (2003) (0)
- 1665P Genomic mutational landscape of solid tumors: Preliminary results from ROME trial (2022) (0)
- Modulation of leukemic cell proliferation by tumor necrosis factor alpha. (1988) (0)
- 28th meeting of the Italian Cancer Society (SIC). New challenges of molecular oncology. (2002) (0)
- Abstract 2298: Cytokine-induced killer cells redirected with anti-CD44v6 chimeric antigen receptor against soft tissue sarcomas (2016) (0)
- Thrombopoietin-stimulated ex vivo expansion of megakakyocyte progenitors of human cord blood (1997) (0)
- Imatinib in 34 patients with steroid-refractory chronic graft-versus-host-disease: final evaluation of the second prospective trial, according to the NIH Consensus criteria for cGvHD (2012) (0)
- P3-07-04: Does Omission of Axillary Dissection after a Positive Sentinel Node Biopsy Influence Indication to Adjuvant Chemotherapy in Operable Breast Cancer Patients? (2011) (0)
- Expression of the hybrid P210 bcr/abl protein in Philadelphia chromosome positive B-lymphoid cell lines. (1989) (0)
- 21 STEM CELLS IN CORD AND NEONATAL BLOOD (1977) (0)
- Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant. (2004) (0)
- Budget impact analysis of the use of lapatinib in the treatment of breast cancer in Italy (2009) (0)
- Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells (2022) (0)
- Analysis of Hohn (HC) and porth-a-cath (PAC) central venous catheters (CVC) adverse events (AEs) and related costs in advanced soft tissue sarcomas (STS) treated with trabectedin (TR) 24-hour (24-h) infusion therapy. (2017) (0)
- Session D: Organization D1 ORGANIZATIONAL MODEL OF CENTRALIZED PHARMACY FOR THE PREPARATION OF CANCER THERAPIES PERSPECTIVE (2004) (0)
- Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer (2020) (0)
- 133 mTOR is a druggable molecule in Malignant Pleural Mesothelioma targeted therapy: antiproliferative effect of sorafenib and everolimus in preclinical models (2010) (0)
- Primitive stem cell biology (2001) (0)
- L02*Multicenter randomized study of Gemcitabine and Oxaliplatin (GEMOX) +/- Panitumumab as First Line Treatment in K-Ras Wild type Advanced Biliary Tract Cancer; the VECTI-BIL study (2015) (0)
- Imaging as a potential tool for subtyping breast cancer (2012) (0)
- Abstract LB-213: The antitumor effect of trabectedin (TR) is potentiated by olaparib (OL) in preclinical models of bone and soft tissue sarcomas (STS). (2013) (0)
- granulocyte-monocyte progenitors Effect of acidic and basic isoferritins on in vitro growth of human (2011) (0)
- Induction chemotherapy with continuous infusion ifosfamide (IFX) and antracyclin in a high dose chemotherapy with peripheral blood stem cell (PBSC) support program in advanced soft tissue sarcomas (STS) (1999) (0)
- 190 Novel cellular immunotherapy with anti-mesothelin CAR-killer lymphocytes against advanced cholangiocarcinoma (2022) (0)
- Role of Hematopoietic Growth Factors on the ex Vivo Expansion of Primitive Cord Blood Stem Cells (1999) (0)
- Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses (2019) (0)
- A form to report pain assessment and monitoring in the oncology clinical record: a Delphi process. (2023) (0)
- Abstract 2812: CSPG4-specific CAR.CIK lymphocyte-based immunotherapy to eliminate HLA class I-defective melanoma tumors (2022) (0)
- Preclinical study of trabectedin (TR) and poly(ADP-ribose)polymerase 1 (PARP-1) inhibitor combination in soft tissue sarcoma (STS). (2017) (0)
- GM-CSF and dose escalation of chemotherapy. (1994) (0)
- Abstract 533: The immune landscape in colon cancer and its changes after radiotherapy (2019) (0)
- Abstract P6-08-49: Do traditional prognostic factors in early breast cancer still have a role in the molecular era? (2015) (0)
- F073-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA (2015) (0)
- TANDEM AUTOGRAFTING-NONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: THE GITMO EXPERIENCE (2007) (0)
- PALETTE: A randomized, double-blind phase III trial of pazopanib versus placebo in patients with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072). (2011) (0)
- Abstract 2290: Effective immunotherapy with cytokine-induced killer cells against autologous melanoma cancer stem cells (2016) (0)
- Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report (2016) (0)
- AUTOGRAFTING FOLLOWED BY NON MYELOABLATIVE TBI-BASED ALLOGRATING FOR TREATMENT OF MULTIPLE MYELOMA: A MULTI-CENTER TRIAL (2002) (0)
- LONG TERM FOLLOW UP OF A COMPARISON OF NONMYELOABLATIVE ALLOGRAFTING WITH AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (2009) (0)
- Errata: (Anticancer Research (2014) 34, 5 (2657)) (2014) (0)
- Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report (2019) (0)
- Predictive biomarkers of trabectedin (TR) and olaparib (OL) synergism in preclinical models of bone and soft tissue sarcoma (BSTS). (2014) (0)
- Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Massimo Aglietta?
Massimo Aglietta is affiliated with the following schools: